A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
about
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@en
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@nl
type
label
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@en
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@nl
prefLabel
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@en
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@nl
P2093
P2860
P356
P1476
A genetic variant in Rassf1a p ...... 3 and JACCRO 05 and 06 trials.
@en
P2093
M D Berger
S Matsusaka
S Stremitzer
P2860
P2888
P356
10.1038/TPJ.2016.69
P577
2016-10-04T00:00:00Z